Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be ...

Lysosomal storage diseases in dogs are caused by a lack of certain enzymes. Subsequently, the condition often affects the nervous system. Thankfully, the condition is very rare — although the ...

Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, ...

December 2, 2011 — Lysosomal storage disorders such as Fabry's disease and Pompe's disease are much more common than previously thought, particularly atypical later-onset forms, a new study suggests.

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of ...

Please provide your email address to receive an email when new articles are posted on . An Italian pharmaceutical company and a Boston-area biotechnology research firm announced a partnership to ...

Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...

Sanofi’s venglustat showed a meaningful change in patients with Gaucher disease but not in patients with Fabry disease.

Functioning brain cells need a functioning system for picking up the trash and sorting the recycling. But when the cellular ...

Together with colleagues from Stanford University, USA, researchers at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) have, for the first time, created a comprehensive cell ...

In the past week, two announcements from the drug discovery world have had Insilico Medicine’s generative artificial intelligence (AI) target discovery engine, PandaOmics, front and center. The first ...

Knowing which lysosomal proteins are enriched in which brain cell types will help better understand contribution to neurological disorders.